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Amyotrophic lateral sclerosis (ALS) is a pro-
gressive neurodegenerative disease affecting the
motor neurons of the spinal cord and brain.
Typically, the disease is rapidly fatal; most
individuals die within 2–3 years of diagnosis,
often from respiratory failure (Mitchell and
Borasio 2007). However, survival is variable,
with some individuals living ≥ 10 years
(del Aguila et al. 2003). The reasons for this
variability are largely unknown. Factors related
to shorter survival include older age, female
sex, bulbar onset, and decreased time from
symptom onset to diagnosis (del Aguila et al.
2003), but other factors likely play a role.
The etiology of ALS is also not well under-
stood, but the disease is generally considered to
be a result of the interplay between genetic and
environmental factors (Mitchell and Borasio
2007). Sporadic ALS is not strongly related to
superoxide dismutase (SOD1) or other genes
associated with familial ALS, although varia-
tion in these or other genes may increase sus-
ceptibility (Kunst 2004; Mitchell and Borasio
2007). No environmental exposure has been
convincingly demonstrated to play a role in
ALS (Armon 2003), but some evidence impli-
cates smoking (Kamel et al. 1999), pesticides
(McGuire et al. 1997), electromagnetic ﬁelds
(Savitz et al. 1998), and heavy metals (Kamel
et al. 2005).
In a previous study (Kamel et al. 2002),
we found that ALS risk was associated with
both blood and bone levels of lead as well as
with occupational lead exposure. Other studies
have also reported associations of ALS risk
with lead exposure (reviewed by Kamel et al.
2005), and a recent study found a cluster of
ALS cases in proximity to an active lead
smelter in Missouri (Turabelidze et al. 2008).
In the present study we followed cases from
our previous study (Kamel et al. 2002) to
evaluate the relationship of lead exposure to
ALS mortality. Our expectation was that lead
exposure would shorten survival; surprisingly,
we found that lead exposure was associated
with longer survival.
Materials and Methods
We conducted a case–control study in New
England, USA, in 1993–1996 (Kamel et al.
2002). Sequential ALS cases were recruited
from two Boston, Massachusetts, ALS clinics;
71% of eligible cases participated in the study
(n = 110). Diagnosis of ALS by board-certiﬁed
neurologists specializing in motor neuron dis-
ease was based on World Federation of
Neurology El Escorial criteria, that is, on the
presence of progressive disease with both upper
and lower motor neuron signs (Brooks 1994).
Cases were required to live in New England, to
be mentally competent, and to speak English.
About 85% of cases were enrolled in the study
within 1 year of diagnosis, and the remainder
within 2 years; 46% were enrolled within
1 year of symptom onset, 73% within 2 years,
and 86% within 3 years.
Data collection involved an in-person
structured interview and measurements of
blood and bone lead; study procedures were
completed within 1 month of enrollment.
The interview collected information on demo-
graphics, lifestyle, occupational history, medi-
cal history, and occurrence of ALS in
ﬁrst-degree relatives; its main focus was expo-
sure to lead. We based self-reported occupa-
tional exposure to lead on the question, “On
any of your jobs, were you exposed 10 times or
more to lead in any form (fumes, dust, parti-
cles)?” We also recorded dates of first ALS
diagnosis and ﬁrst experience of related symp-
toms in this interview. We extracted informa-
tion on respiratory function [forced vital
capacity (FVC)] from medical records and
available only for a subset of cases (n = 68). We
measured bone lead in tibia and patella using
K X-ray fluorescence and blood lead using
atomic absorption spectrometry (Kamel et al.
2002). Blood lead measurements were avail-
able for 107 cases and bone lead measurements
for 104. We collected whole blood as a source
of DNA, and genotyped the K59N polymor-
phism (rs1800435) in the δ-aminolevulinic
acid dehydratase (ALAD) gene using poly-
merase chain reaction–restriction fragment
length polymorphism (Kamel et al. 2003).
For the present study, we obtained infor-
mation on date and cause of death by search-
ing the National Death Index (NDI) Plus
(National Center for Health Statistics,
Hyattsville, MD) through 31 December 2003.
We considered five items in identifying
matches to NDI Plus data: social security
number, birth date (day, month, and year),
ﬁrst name, last name, and sex. Seventy-eight
individuals were complete matches, with all
five items identical. Nineteen were partial
matches: either four items were identical, or
three items were identical and no more than
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BACKGROUND: Reasons for the variability in survival among ALS cases are unknown but may
include exposure to environmental neurotoxicants.
OBJECTIVES: We aimed to determine whether lead exposure, assessed by measuring blood and bone
lead levels, is associated with survival in amyotrophic lateral sclerosis (ALS).
METHODS: We evaluated the relationship of lead exposure to ALS survival in 110 cases from a
case–control study conducted in New England in 1993–1996 that included measurements of blood
and bone lead. We retrieved information on date and cause of death through 31 December 2003
from the National Death Index Plus and the Social Security Administration Death Index. We eval-
uated the relationship of survival to lead exposure using Cox proportional hazard analysis, with
adjustment for age, sex, and smoking.
RESULTS: We found mortality data for 100 of 110 cases; 93 of 100 death certiﬁcates mentioned
ALS. Median survival from diagnosis to death was 28 months. Shorter survival was associated with
older age at diagnosis, female sex, bulbar onset, shorter interval between symptom onset and diag-
nosis, and reduced lung function. Shorter survival from diagnosis to death had a weak inverse asso-
ciation with blood lead (hazard ratio = 0.9; 95% confidence interval, 0.8–1.0) and a stronger
inverse association with patella lead (0.5; 0.2–1.0) and tibia lead (0.3; 0.1–0.7); similar results were
found for survival from symptom onset to death.
CONCLUSIONS: These results suggest that lead exposure is associated with longer survival in ALS
cases and, if conﬁrmed, may shed light on mechanisms involved in disease progression.
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different. Four poor matches did not meet
these criteria, and we found no NDI matches
for nine individuals; for 3 of these 13 individu-
als, death dates were found by searching the
records of the Social Security Administration
and death certificates were retrieved. Thus,
date and cause of death were available for
100 of 110 cases (91%). Comparing the
10 individuals without mortality data with the
100 with data, the former were slightly
younger (median age, 57 vs. 61 years) and
more likely to be male (8 of 10 vs. 59 of 100),
but blood and bone lead levels in the two
groups did not differ. ALS was recorded on
the death certiﬁcate as either an underlying or
a contributing cause of death, for 93 of the
100 cases (93%) for whom we had informa-
tion on date and cause of death.
We used Cox proportional hazard analysis
to estimate hazard ratios (HRs) and 95% con-
ﬁdence intervals (CIs) using SAS, version 9.1
(SAS Institute Inc., Cary, NC). We con-
ducted two parallel analyses using as the
dependent variable interval from diagnosis to
death or interval from symptom onset to
death, both deﬁned based on interview data.
The 10 cases without mortality data were
assumed to be still living and were censored at
the end of follow-up; censored individuals
contributed person-time to the denominator
up to the time of censoring but no events to
the numerator. Sensitivity analyses either cen-
soring these individuals at the date of their
interview or excluding them gave results simi-
lar to those presented below. We censored
7 individuals whose death certificates made
no mention of ALS (5 of whom were exact
matches) at their date of death, again allowing
them to contribute to the denominator but
not the numerator. Results were similar if we
assumed that these seven individuals had in
fact died of ALS and counted them in the
numerator.
We modeled blood and bone lead levels as
continuous variables after transformation
using log2([Pb] + 32), where [Pb] is lead con-
centration (Kamel et al. 2002). Because age,
sex, and smoking may be related to both lead
exposure and ALS, all models included age at
interview (as a log-transformed continuous
variable), sex, and a dichotomous variable for
ever having smoked; considering smoking sta-
tus (never, former, current) at the time of the
interview gave similar results. Additional fac-
tors considered as potential confounders
included education (high school or less vs.
greater than high school); body mass index
(BMI; dichotomized at the lowest quartile)
and physical activity level at the time of the
interview (hours of sitting, lying down, or
sleeping per day, continuous); site of disease
onset (bulbar vs. limb); the interval between
symptom onset and diagnosis (dichotomized
at the median); history of ALS in ﬁrst-degree
relatives; and respiratory function (FVC,
dichotomized at the median), assessed in
models excluding individuals with missing
data. None of these variables changed the
effect estimates for lead by > 10%, so none
was included in ﬁnal models.
We considered potential effect modifica-
tion by age, sex, or interval between symptom
onset and diagnosis using stratified models.
Too few individuals had bulbar onset, family
history of ALS, or diagnosis > 1 year before
enrollment for us to consider these groups
separately, but we ran models restricted to
individuals without these characteristics.
The study was approved by the institu-
tional review boards of participating institu-
tions, and the participants provided written
informed consent.
Results
The median (range) interval between ﬁrst diag-
nosis and death for the 100 cases with death
certiﬁcate information was 28 (6–121) months;
the median interval between symptom onset
and death was 40 (9–207) months. Personal
characteristics were associated with both the
diagnosis-to-death and the symptoms-to-death
intervals. Older individuals and women sur-
vived for a shorter time, whereas those who
had ever smoked, had no more than a high
school education, or were in the lowest quartile
of BMI lived longer, although all results were
imprecise (Table 1). Clinical characteristics
were also related to both diagnosis-to-death
and symptoms-to-death intervals: cases with a
longer interval between symptom onset and
diagnosis or a family history of ALS lived
longer, whereas those with bulbar onset or
reduced FVC survived for a shorter time;
again, results were imprecise (Table 1).
Blood and bone lead levels of cases were
higher than those of controls in the original
case–control study (Kamel et al. 2002). After
adjustment for age, sex, and area within New
England, mean ± SE blood lead levels were
5.2 ± 0.4 µg/dL for cases and 3.4 ± 0.4 µg/dL
for controls; patella lead levels were 20.3 ± 2.1
µg/g for cases and 16.7 ± 2.0 µg/g for con-
trols; and tibia lead levels were 14.9 ± 1.6
µg/g for cases and 11.1 ± 1.6 µg/g for con-
trols. Both blood and bone lead levels were
inversely associated with survival after adjust-
ment for age, sex, and smoking. The relation-
ship with blood lead was relatively weak, but
both patella and tibia lead were strongly asso-
ciated with intervals of both diagnosis to
death and symptoms to death (Table 2).
Further adjustment of lead models for educa-
tion, BMI, physical activity, bulbar onset,
interval between symptom onset and diagno-
sis, family history of ALS, or FVC did not
alter the association of lead levels with sur-
vival for either outcome. In models of the
diagnosis-to-death interval including any one
of these variables, HRs for blood lead were
0.91–0.96, HRs for patella lead were 0.4–0.6,
and HRs for tibia lead were 0.1–0.4; results
Kamel et al.
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Table 1. Relationship of survival of ALS cases to personal and clinical characteristics, New England,
1993–1996.
Adjusted HR (95% CI)a
Characteristic Median (range) or no. (%) Diagnosis to death Symptoms to death
Age at enrollment (years) 60 (30–79) 2.0 (0.8–4.8) 1.4 (0.6–3.4)
Sex
Male 67 (61) 1.0 (referent) 1.0 (referent)
Female 43 (39) 1.4 (0.9–2.2) 1.4 (0.9–2.1)
Ever smoked
No 32 (29) 1.0 (referent) 1.0 (referent)
Yes 78 (71) 0.6 (0.4–1.0) 0.7 (0.5–1.2)
Education
> High school 72 (65) 1.0 (referent) 1.0 (referent)
≤ High school 38 (35) 0.7 (0.4–1.1) 0.7 (0.4–1.1)
BMI
> 22.2 83 (75) 1.0 (referent) 1.0 (referent)
≤ 22.2 27 (25) 0.7 (0.4–1.1) 0.7 (0.4–1.2)
Physical activity (hours of inactivity per day) 17 (7–24) 1.0 (1.0–1.1) 1.0 (0.9–1.0)
Bulbar onset
No 88 (80) 1.0 (referent) 1.0 (referent)
Yes 22 (20) 1.4 (0.8–2.4) 1.3 (0.8–2.3)
Symptom onset to diagnosis (months)
≤ 8 56 (51) 1.0 (referent) 1.0 (referent)
> 8 54 (49) 0.6 (0.4–1.0) 0.4 (0.2–0.6)
Family history of ALS
No 102 (93) 1.0 (referent) 1.0 (referent)
Yes 8 (7) 0.5 (0.2–1.2) 0.6 (0.2–1.4)
FVC
> 2.8 L 34 (50) 1.0 (referent) 1.0 (referent)
≤ 2.8 L 34 (50) 1.8 (0.9–3.6) 1.5 (0.8–3.1)
Missing 42
aHRs and 95% CIs were calculated with Cox proportional hazard analysis; all models included age, sex, and ever smoked.were similar for the symptoms-to-death inter-
val (data not shown). Self-reported occupa-
tional lead exposure was also inversely
associated with survival, although results were
imprecise (Table 2).
We evaluated the relationship of ALS sur-
vival to each lead variable after stratiﬁcation by
age, sex, or the interval between symptom
onset and diagnosis. None of these variables
substantially modiﬁed the association of ALS
survival with blood or tibia lead, but we
observed the association with patella lead pri-
marily in individuals > 60 years of age, in men,
and in those with an interval of no more than
8 months between symptom onset and diagno-
sis (Table 2). Exclusion of individuals with a
family history of ALS, bulbar onset, or diagno-
sis > 1 year before enrollment did not affect
results substantially. In models of the
diagnosis-to-death interval restricted by any
one of these three variables, HRs were as fol-
lows: for blood lead, 0.9; for patella lead,
0.3–0.5; and for tibia lead, 0.2–0.4. Results
were similar for the symptoms-to-death inter-
val (data not shown).
Blood and bone lead levels were correlated
(Spearman r = 0.4 for blood and patella,
0.4 for blood and tibia, and 0.5 for patella
and tibia), so we considered relationships
among effects of the three lead variables by
modeling them together. For the diagnosis-
to-death interval, HRs (95% CIs) were 0.9
(0.8–1.1) for blood lead, 0.8 (0.3–1.7) for
patella lead, and 0.4 (0.2–0.9) for tibia lead in
a model including all three variables. For the
symptoms-to-death interval, HRs were 0.9
(0.8–1.0) for blood lead, 0.9 (0.4–2.2) for
patella lead, and 0.4 (0.2–0.9) for tibia lead.
Blood lead levels were not associated with
the ALAD K59N polymorphism, but bone
lead levels were lower in carriers of the poly-
morphism (homozygotes plus heterozygotes)
compared with wild-type homozygotes
(patella, 7.3 vs. 14 µg/g; tibia, 8.6 vs. 14 µg/g).
The polymorphism was not associated with
either the diagnosis-to-death or the symptoms-
to-death interval, nor did it affect the associa-
tion of any of the three lead variables with
survival (data not shown).
Discussion
In this study, we found that lead exposure was
associated with longer survival in ALS cases.
Results were similar whether we considered
the interval between ﬁrst diagnosis and death
or the interval between symptom onset and
death. The strongest association was with
tibia lead, although blood and patella lead
and self-reported occupational exposure to
lead were also related to survival.
This observation contrasts with our previ-
ous ﬁnding that lead exposure was associated
with increased risk of ALS (Kamel et al. 2002),
thus suggesting that lead exposure may have
different effects on ALS onset and progression.
This apparently paradoxical result may have a
biological explanation. Recent studies in a
mouse model of inherited ALS have suggested
that onset is related to motor neuron function,
whereas progression is regulated by neuroglia
(Boillee et al. 2006). Thus, it is possible that
the two processes respond differently to neuro-
toxic exposures. For example, lead might injure
motor neurons but stimulate glial cells to pro-
vide trophic support to neurons and delay cell
death. Support for this hypothesis comes from
a recent study showing that although lead was
toxic to motor neurons in monoculture, it
increased the trophic activity of astrocyte-
conditioned culture medium for motor neu-
rons (Barbeito et al. 2005). The same study
found that lead exposure prolonged survival in
SOD transgenic mice (Barbeito et al. 2005).
Our result is also supported by a previous
study of lead exposure and survival that found
that the 5-year survival rate was 54% in
11 individuals with high lead exposure (based
on self-report) but 16% in 89 individuals with
low or no lead exposure (Campbell et al.
1970). Thus, it is possible that lead-related
ALS involves a mechanism, still unidentiﬁed,
that generally leads to slower progression than
ALS associated with other etiologies.
Alternatively, it is possible that factors
associated with better survival were also associ-
ated with higher lead levels in our study popu-
lation. For example, men have higher lead
levels (Brody et al. 1994) and live longer with
ALS (del Aguila et al. 2003). However,
although survival was associated with blood
and patella lead only in men, it was strongly
related to tibia lead in both men and women.
Confounding by age is unlikely to account for
our results, because older individuals have
higher lead levels (Brody et al. 1994; Hu et al.
1996; Korrick et al. 2002) but live for a
shorter time with ALS (del Aguila et al. 2003);
in the present study, lead was inversely associ-
ated with survival in both younger and older
individuals. We observed associations of lead
with survival after adjustment for age, sex, and
smoking; further adjustment for education,
BMI, or physical activity did not change the
results, suggesting that confounding by these
Lead exposure and ALS survival
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Table 2. Relationship of survival of ALS cases (n = 110) to lead exposure, New England 1993–1996.
Adjusted HR (95% CI)a
Lead exposure/characteristic Median (range) or no. (%) Diagnosis to death  Symptoms to death
Blood lead (µg/dL)b
All 4 (0.5 to 14) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0)
Age (years)
≤ 60 4 (0.5 to 13) 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.3)
> 60  4 (1 to 14) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0)
Sex 
Male  4 (1 to 14) 0.9 (0.8 to 1.0) 0.8 (0.7 to 0.9)
Female 4 (0.5 to 13) 1.1 (0.9 to 1.3) 1.1 (0.9 to 1.3)
Symptom onset to diagnosis (months)
≤ 8  4 (0.5 to 14) 0.9 (0.8 to 1.0) 0.9 (0.8 to 1.0)
> 8  4 (0.5 to 11) 0.9 (0.8 to 1.1) 0.9 (0.8 to 1.1)
Patella lead (µg/g)b
All 15 (0 to 107) 0.5 (0.2 to 1.0) 0.6 (0.3 to 1.2)
Age (years)
≤ 60  11 (1 to 33) 0.2 (0.1 to 1.2) 0.4 (0.1 to 1.7)
> 60  24 (0 to 107) 0.6 (0.3 to 1.3) 0.6 (0.2 to 1.3)
Sex 
Male  16 (0 to 107) 0.1 (0.0 to 0.3) 0.1 (0.0 to 0.3)
Female 14 (0 to 59) 1.0 (0.3 to 3.3) 1.6 (0.5 to 5.2)
Symptom onset to diagnosis (months)
≤ 8  18 (0 to 107) 0.2 (0.1 to 0.6) 0.2 (0.1 to 0.6)
> 8  14 (0 to 46) 0.5 (0.2 to 1.5) 0.5 (0.2 to 1.5)
Tibia lead (µg/g)b
All 13 (–6 to 61) 0.3 (0.1 to 0.7) 0.3 (0.2 to 0.7)
Age (years)
≤ 60  11 (0 to 29) 0.3 (0.1 to 1.2) 0.3 (0.1 to 1.4)
> 60  20 (–6 to 61) 0.2 (0.1 to 0.7) 0.2 (0.1 to 0.6)
Sex 
Male  13 (0 to 61) 0.2 (0.1 to 0.8) 0.2 (0.1 to 0.8)
Female 14 (–6 to 47) 0.4 (0.1 to 1.1) 0.4 (0.2 to 1.4)
Symptom onset to diagnosis (months)
≤ 8  13 (0 to 61) 0.3 (0.1 to 0.9) 0.3 (0.1 to 1.0)
> 8  14 (–6 to 47) 0.3 (0.1 to 0.7) 0.2 (0.1 to 0.6)
Occupational lead exposure
No 67 (66) 1.0 (referent) 1.0 (referent)
Yes 35 (34) 0.7 (0.5 to 1.2) 0.7 (0.4 to 1.2)
Missing 8
aHRs and 95% CIs were calculated with Cox proportional hazard analysis; models included age, sex, and ever smoked,
except for sex-stratiﬁed models, which included age and ever smoked. bHRs were calculated for each µg/dL blood lead
and for each doubling of bone lead, as described in the “Materials and Methods.”characteristics did not account for our find-
ings. Adjustment for or stratiﬁcation by clini-
cal characteristics, including bulbar onset,
diagnostic delay, family history of ALS, or res-
piratory dysfunction, also did not affect the
association of lead with survival.
A third possible explanation for the appar-
ently paradoxical influence of lead on ALS
onset and survival is that one of the two asso-
ciations might be artifactual. Biases of various
kinds can arise in studies of factors that poten-
tially inﬂuence both disease incidence and dis-
ease progression (Glymour 2007). For
example, if lead exposure were related not to
ALS risk but in fact to slower progression
(longer survival), or to a more benign (less
symptomatic) form of disease, then lead-
exposed cases might be more likely to enroll in
the study. In contrast, no such selective pres-
sure would exist for controls, and therefore
ALS cases as a group might have higher lead
levels than controls, creating the appearance of
a positive association with incidence (risk).
Factors consistently related to ALS survival in
previous studies include age, bulbar onset,
short diagnostic delay, and respiratory dys-
function (Czaplinski et al. 2006; del Aguila
et al. 2003; Paillisse et al. 2005). Other factors
potentially related to survival are sex, diagnos-
tic certainty, score on the ALS Functional
Rating Scale or similar instruments, and rate
of progression after diagnosis (Chio et al.
2002; Guiloff and Goonetilleke 1995; Millul
et al. 2005; Turner et al. 2002). Consistent
with these reports, we found that older age,
female sex, decreased interval between symp-
tom onset and diagnosis, bulbar onset, and
reduced FVC shortened survival.
Previous studies have indicated that diag-
nosed ALS is usually reported on death certiﬁ-
cates, although there is some variation between
and even within countries. For individuals
with ALS who could be traced, ALS was men-
tioned on the death certiﬁcate for 95% of cases
in Sweden (Gunnarsson and Palm 1984), 75%
in Italy (Chio et al. 1992), 94% in Scotland
(Chancellor et al. 1993), and 86% in England
(Dean et al. 1994). One study found that ALS
was listed on the death certiﬁcate for 67% of
cases in northern Italy but only 52% in south-
ern Italy (Ragonese et al. 2004). We were able
to identify only one study conducted in the
United States, which reported that ALS was
mentioned on the death certiﬁcate for 72% of
cases (Hoffman and Brody 1971). In the pre-
sent study, we found mortality data for 91% of
cases from our original study. The NDI search
was conducted 7–10 years after enrollment, so
it is possible that some of the others were still
living, particularly because cases without mor-
tality data were slightly younger and more
likely to be male—characteristics associated
with longer survival. Cases without mortality
data had lead levels similar to those we traced,
reducing concern about bias. ALS was listed on
the death certificate for 93% of the traced
cases, comparable to rates in Sweden and
Scotland. These results suggest that death cer-
tificates are a reasonable source of mortality
data for ALS.
A major strength of the present study is the
availability of biological measures of lead expo-
sure. Blood lead is considered to reﬂect recent
exposure, and bone lead to reﬂect cumulative
exposure, especially lead in cortical bone such
as tibia, which has a half-life of decades (Hu
et al. 2007). The strong association with tibia
lead thus suggests that cumulative rather than
recent exposure is related to survival.
Study limitations include the small sample
size. However, our estimates of the associations
of lead with survival were precise, particularly
for tibia lead, indicating that our study had suf-
ﬁcient power to address its hypothesis. We had
no information on tracheotomy or other treat-
ments that may have prolonged life in some
patients, but such treatment is likely to be
independent of lead exposure and thus unlikely
to account for its relationship with survival.
We also lacked information on disability from
the ALS Functional Rating Scale or similar
instrument. Because cases for the study were
drawn from two tertiary care centers, results
may not be generalizable to the population as a
whole. However, our study was comparable
with others in the length of survival as well as
factors affecting survival (Czaplinski et al.
2006; del Aguila et al. 2003; Mitchell and
Borasio 2007; Paillisse et al. 2005).
In conclusion, we found that greater lead
exposure was associated with longer survival
in ALS cases, independent of other personal
and clinical characteristics affecting survival or
lead exposure. The relationship with tibia lead
in particular was strong and consistent, sug-
gesting a role for cumulative lifetime expo-
sure. These results must be interpreted with
caution, given the unexpected nature of the
finding and the small size of the study, and
await replication. If conﬁrmed, these ﬁndings
may shed light on mechanisms involved in
disease progression and could suggest a basis
for therapies that prolong survival.
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